The U.S. Food and Drug Administration’s Covid strain selection for the next round of shots puts Pfizer, Moderna, and Novavax on track to deliver new jabs in time for the fall — a decisive win for the vaccine makers as they gear up to compete against one another.
The vaccine will target XBB 1.5, which has been the dominant COVID subvariant in the US recently. As COVID vaccines become a yearly thing, manufacturers will work with the FDA to target dominant variants to make the vaccines effective.